89 Zr-bevacizumab PET imaging in metastatic renal cell carcinoma patients before and during antiangiogenic treatment.
Lists
Only you see this
Abstract
10581 Background: Renal cell cancer (RCC) is characterized by high VEGF production leading to excessive angiogenesis. To visualize VEGF, we performed serial 89 Zr-bevacizumab-PET scans before and during antiangiogenic treatment in RCC patients. Methods: Metastatic (m) RCC patients who received sunitinib (50 mg once daily, 4 out of 6 weeks) or bevacizumab (10 mg/kg every 2 weeks) plus interferon (IFN 3-9 MU 3x/week), underwent 89 Zr-bevacizumab-PET scans at baseline and after 2 and 6 weeks, and CT scans at baseline and every 3 months. Tracer uptake in tumor lesions was quantified with maximum Standardized Uptake Value (SUVmax). Relationship between baseline and Δ SUVmax and time to progression (TTP) was analyzed. Wilcoxon test was used to compare scans, Kaplan-Meier method for survival analysis. Results: 22 out of 26 patients were evaluable, 11 per treatment. On 89 Zr-bevacizumab-PET, 131 out of 231 lesions ≥ 10 mm (detection limit) were visible and 125 quantifiable. Mean SUVmax at baseline was 10.1 (SD 8.4; range 2.3 - 46.9). During bevacizumab/IFN treatment, SUVmax consistently decreased (mean decrease 47.0% 95% CI 39.1-54.9, P<0.0001) at 2 weeks with a further decrease of 9.7% (95% CI 0.86-18.5, P=0.016) at 6 weeks. After 2 weeks sunitinib, there was only a modest decrease in mean SUVmax (14.6%, 95% CI 1.57-27.63, P=0.0064) with a wide range (-80.4% to +269.9%) and an overshoot of 84.4% (95% CI 47.8-120.9, P=0.0001) after 2 drug free weeks. TTP was longer in (n=15) patients with baseline SUVmax > 11.1 (highest normal tissue uptake) in the 3 most intense lesions than in those with a lower value (median 89.7 vs 22.8 weeks, HR 0.16, 95% CI 0.04 - 0.70). TTP was longer in patients (n=11) with an absolute Δ SUVmax >6.00 in the most intense lesion at 2 weeks (HR 0.25, 95% CI 0.06-0.98). Conclusions: 89 Zr-bevacizumab-PET visualizes tumor lesions in mRCC patients. Different changes in tumor tracer uptake after start of bevacizumab/IFN versus sunitinib indicate that these drugs induce different angiogenic responses. High baseline SUVmax and large change in SUVmax corresponded with longer TTP, suggesting that 89 Zr-bevacizumab-PET may help to identify patients who benefit the most from antiangiogenic treatment.
BibTeX
@article{oosting2012sup,
author = {Sjoukje F. Oosting and Adrienne H. Brouwers and Suzanne C. van Es and Wouter B. Nagengast and Thijs H. Oude Munnink and Marjolijn N. Lub–de Hooge and Harry Hollema and Johan R. de Jong and Igle J. de Jong and Sanne de Haas and Stefan Scherer and Wim J. Sluiter and Rudi Dierckx and Alphons H.H. Bongaerts and Jourik A. Gietema and Elisabeth G.E. de Vries},
title = {{<sup>89 </sup>Zr-bevacizumab PET imaging in metastatic renal cell carcinoma patients before and during antiangiogenic treatment.}},
journal = {Journal of Clinical Oncology},
year = {2012},
doi = {10.1200/jco.2012.30.15\_suppl.10581},
}Loading related content...